Scarica l'app Stockscreener
1.74
4.82%
0.08
Dopo l'orario di chiusura:
1.75
0.01
+0.57%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ZNTL Giù?
Forum
Previsione
Precedente Chiudi:
$1.66
Aprire:
$1.7
Volume 24 ore:
3.13M
Relative Volume:
1.76
Capitalizzazione di mercato:
$124.00M
Reddito:
-
Utile/perdita netta:
$-292.19M
Rapporto P/E:
-0.3833
EPS:
-4.54
Flusso di cassa netto:
$-208.41M
1 W Prestazione:
-21.62%
1M Prestazione:
-42.57%
6M Prestazione:
-55.27%
1 anno Prestazione:
-85.32%
Intervallo 1D:
$1.69
$1.79
Intervallo di 1 settimana:
$1.66
$2.52
Portata 52W:
$1.66
$18.07
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Nome
Zentalis Pharmaceuticals Inc
Settore
Industria
Telefono
(858) 263-4333
Indirizzo
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Confronta ZNTL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.74 | 124.00M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-12 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2024-06-20 | Downgrade | UBS | Buy → Neutral |
| 2024-06-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-06-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Downgrade | Wedbush | Neutral → Underperform |
| 2024-06-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-11-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Iniziato | Cowen | Outperform |
| 2022-04-06 | Iniziato | Wells Fargo | Overweight |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-29 | Iniziato | Oppenheimer | Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-01-20 | Iniziato | Wedbush | Outperform |
| 2020-09-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-28 | Iniziato | Guggenheim | Buy |
| 2020-04-28 | Iniziato | Jefferies | Buy |
| 2020-04-28 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Zentalis Pharmaceuticals Inc Borsa (ZNTL) Ultime notizie
FY2029 Earnings Forecast for ZNTL Issued By HC Wainwright - MarketBeat
Equities Analysts Offer Predictions for ZNTL FY2029 Earnings - MarketBeat
Zentalis stock price target cut to $10 by H.C. Wainwright - MSN
Wells Fargo & Company Has Lowered Expectations for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price - Defense World
Zentalis stock plunges to 52-week low of $1.76 amid market challenges - MSN
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $6.00 Price Target at Wells Fargo & Company - MarketBeat
Jefferies cuts Zentalis stock target to $2.50; maintains hold - MSN
Vanguard Group Inc. Reduces Stake in Zentalis Pharmaceuticals Inc. - GuruFocus.com
Short Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Decreases By 17.5% - MarketBeat
HC Wainwright Issues Pessimistic Forecast for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price - Defense World
Zentalis price target lowered to $6 from $8 at Wells Fargo - MSN
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $10.00 Price Target at HC Wainwright - MarketBeat
Zentalis Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:ZNTL) - MarketBeat
Zentalis price target lowered to $10 from $20 at Oppenheimer - Yahoo Finance
Oppenheimer cuts Zentalis stock target to $10, maintains rating - MSN
Zentalis to cut 40% of workforce, focus on azenosertib - MSN
UBS Group Issues Pessimistic Forecast for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price - Defense World
Zentalis Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:ZNTL) - Defense World
Oppenheimer cuts Zentalis stock target to $10, maintains rating By Investing.com - Investing.com UK
Zentalis Pharmaceuticals Announces New Study for Azenosertib - TipRanks
Zentalis reports progress in ovarian cancer study - MSN
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer - The Manila Times
Zentalis Pharmaceuticals Shares Updated Clinical Data - GlobeNewswire
Breakthrough: New Ovarian Cancer Drug Achieves Remarkable 35% Success Rate - StockTitan
Zentalis Pharmaceuticals to Cut 40% of Workforce -January 29, 2025 at 03:41 am EST - Marketscreener.com
Zentalis Pharmaceuticals Restructures to Advance Oncology Product - TipRanks
Zentalis to Cut 40% of Workforce to Back Development of Cancer-Drug Azenosertib - MarketWatch
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development - GlobeNewswire
Major Shakeup at Zentalis: Cancer Drug Developer Slashes Jobs to Double Down on Breakthrough Treatment - StockTitan
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Lowered to $2.20 at UBS Group - MarketBeat
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns “Neutral” Rating from Wedbush - Defense World
Zentalis stock plunges to 52-week low, hits $2.16 - MSN
Zentalis Pharmaceuticals' (ZNTL) "Neutral" Rating Reaffirmed at Wedbush - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by JPMorgan Chase & Co. - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Barclays PLC - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Rating of “Hold” from Brokerages - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Down 17.5% in December - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update - MarketBeat
Why Zentalis Pharma Is Worth Watching - RTTNews
Zentalis stock plunges to 52-week low of $2.64 amid market challenges - Investing.com Canada
Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Zentalis Pharmaceuticals, Inc. Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies - Marketscreener.com
Zentalis Gets FDA Fast-Track Designation for Azenosertib - MarketWatch
Zentalis Pharmaceuticals Announces Azenosertib Fast Track - GlobeNewswire
Zentalis' Cancer Drug Azenosertib Receives FDA Fast Track Status for Ovarian Cancer Treatment - StockTitan
Geode Capital Management LLC Has $4.76 Million Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Barclays PLC Buys 11,748 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Jane Street Group LLC Sells 11,796 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals chief scientific officer sells $13,762 in stock By Investing.com - Investing.com Australia
Zentalis Pharmaceuticals Inc Azioni (ZNTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):